Summary:

In an effort to boost pharmaceutical research and development in India, Mankind Pharma and Denovo Sciences have joined to build an AI-driven drug discovery initiative. The partnership accelerates early-stage drug discovery, enhances lead candidate selection, and shortens development timeframes by fusing Denovo Sciences' AI technology with Mankind Pharma's research experience. AI-generated molecular analysis will be supplemented by ongoing scientific validation using a human-in-the-loop technique to improve research efficiency and accuracy. It is anticipated that the program will increase trial success rates, cut down on time spent on less promising compounds, and lessen development expenses. Additionally, it draws attention to India's expanding use of AI in the life sciences, which promotes innovation, improved healthcare outcomes, and leadership in pharmaceutical research worldwide.

Source: IBEF

Disclaimer: The information on this website comes from the India Brand Equity Foundation (IBEF), a reliable source for thorough insights into numerous areas of the Indian economy. While we aim to offer accurate and up-to-date information, the views, opinions, and analyses stated herein are solely those of the authors and contributors and do not necessarily represent IBEF's official stance or position. Readers should check information from credible sources and use their own discretion when relying on content provided on this site. We assume no responsibility or liability for the supplied content, including its accuracy, completeness, and usefulness.